|Bid||18.04 x 800|
|Ask||18.05 x 1800|
|Day's Range||17.54 - 18.31|
|52 Week Range||16.65 - 37.75|
|Beta (5Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 22, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.75|
It looks like investors may be running out of patience with Alkermes, a biotech with drugs on the market to treat alcohol dependence and schizophrenia.
Alkermes (ALKS) delivered earnings and revenue surprises of 25.76% and 1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2019 and provided financial expectations for 2020.
We strongly recommend that investors take advantage of the weakness and buy Alkermes (ALKS), explains John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter.
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 13, 2020, to discuss the company's fourth quarter and year-end 2019 financial results. Management will also discuss financial expectations for 2020 and provide an update on the company.
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and for the treatment of bipolar I disorder. ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of Nov. 15, 2020.
2018's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the […]
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00 p.m. ET/5:00 p.m. GMT) from the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 9:30 a.m. PT (12:30 p.m. ET/5:30 p.m. GMT).The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.
Alkermes (ALKS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.